The resistance spectrum of escherichiacoli in bloodstream infection

Dan YAO,Fangyou YU,Xiaoying HUANG,Xiaomei XU,Liangxing WANG
DOI: https://doi.org/10.3969/j.issn.2095-9400.2014.12.016
2014-01-01
Abstract:Objective: To investigate the drug resistance of escherichiacoli isolated from patients with bloodstream infection to commonly used antibiotics, and to provide reference for clinical anti-infective drug therapy.Methods: The France Bio-Merieux company VITEK-60 compact automatic bactecial identiifcation in-strument was employed to identify the bactecia. According to the (NCCLS) 2005, the double disk conifrmatory test were adopted to detect ESBLs, and K-B disk diffusion assay was used to determine antibiotic resistance of escherichiacoli.Results: Totally 175 strains of escherichiacoli were isolated from the samples, among them, ESBLs-producing strains accounted for 52.6% (92/175). The drug resistence of ESBL-producing escherichiacoli to ampicillin, cefazolin, ceftriaxone, ceftazidime were 98.9%, 97.8%, 94.6%, 83.7% respectively, which were signiifcantly higher than that of non-ESBL-producing escherichiacoli. The drug resistence of ESBL-producing escherichia coli to trimesulf, ciprolfoxacin, gentamycin, tobramycin, levolfoxacin were 76.1%, 57.6%, 57.6%, 58.7%, 69.6% respectively. The drug resistence rate to piperacillin tazobactam and macrodantin were almost similar in ESBL-producing escherichiacoli and non-ESBL-producing escherichiacoli. And the whole escherichia coli were sensitive to tienam and vancomycin.Conclusion: Escherichiacoli as the major gram-negative bacte-rium led to bloodstream infection, its resistance phenomenon to common antibiotics was serious. It is necessary to pay more attention to the the drug resistance to provide reference for clinical anti-infective drug therapy.
What problem does this paper attempt to address?